Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation



Summary

Genetic variations in both liver transplant donors and recipients impact how the body processes tacrolimus, a crucial immunosuppressant drug, soon after transplantation. Specifically, variations in genes coding for drug metabolizing enzymes (like CYP3A5) and transporters (like ABCB1) influence early tacrolimus pharmacokinetics, affecting how the drug is absorbed, distributed, metabolized, and eliminated. Understanding these genetic differences is important because it can help personalize tacrolimus dosing early on, potentially improving treatment outcomes and reducing the risk of rejection or drug toxicity in liver transplant recipients.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!